Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression | Synapse

October 4, 2023

Ver artículo completo

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression

ARAndreas ReifGoethe University Frankfurt IBIstván BitterSemmelweis University JBJozefien BuyzeGoethe University Frankfurt

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week 8. (Funded by Janssen EMEA; ESCAPE-TRD ClinicalTrials.gov number, NCT04338321.).

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Reif et al. (Wed,) studied this question.

synapsesocial.com/papers/69d6f48dfca0359822aa8e21 https://doi.org/https://doi.org/10.1056/nejmoa2304145

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo